Detail akcie Autolus Thp Sp ADS online

Business Summary: Autolus Therapeutics plc is a United Kingdom-based early commercial-stage biopharmaceutical company developing programmed T cell therapies for the treatment of cancer and autoimmune diseases. The Company has an approved commercial product, AUCATZYL, for the treatment of adult patients with r/r B-ALL. Using a suite of proprietary and modular T cell programming technologies, it is also developing five programs in seven hematological and solid tumor indications and one autoimmune indication. It is engineering precisely targeted, controlled and highly active T cell therapies that are designed to better recognize target cells, break down their defense mechanisms and attack and eliminate these cells. Its product pipeline includes obe-cel (ALLCAR19), obe-cel (CAROUSEL), AUTO1/22 (CARPALL), AUTO4 (LibrA T1), AUTO6 (MAGNETO), AUTO5, AUTO8 (MCARTY) and AUTO9. AUTO4 and AUTO5 are two programmed T cell therapies for the treatment of peripheral T-cell lymphoma targeting TRBC 1 and TRBC 2.
Financial Summary: BRIEF: For the six months ended 30 June 2025, Autolus Therapeutics PLC (ADR) revenues increased from $10.1M to $29.9M. Net loss increased 6% to $118.1M. Revenues reflect United States segment increase from $0K to $29.9M. Higher net loss reflects business of developing and commercializing gene therapies segment loss increase of 29% to $126.5M. Basic Earnings per Share excluding Extraordinary Items increased from -$0.46 to -$0.44.